LGND — Ligand Pharmaceuticals Cashflow Statement
0.000.00%
- $3.73bn
- $3.51bn
- $167.13m
- 88
- 12
- 99
- 74
Annual cashflow statement for Ligand Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -2.98 | 57.1 | -33.4 | 52.2 | -4.03 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 61 | 31.4 | 33.3 | -16.4 | 62.3 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -10.1 | -52.2 | 65.7 | -34.4 | 19.4 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | 54.6 | 78.8 | 138 | 49.6 | 97 |
| Capital Expenditures | -4.46 | -8.76 | -17.9 | -64.3 | -1.82 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 236 | 39.3 | 182 | 52.6 | -142 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Sale of Intangible Assets | |||||
| Change in Net Intangibles | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 232 | 30.5 | 164 | -11.7 | -144 |
| Financing Cash Flow Items | -3.81 | 11.9 | -18.2 | -5.5 | -5.56 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -311 | -138 | -276 | -59.9 | 97.1 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -24.3 | -28.4 | 25.5 | -22.1 | 49.4 |